optimizing management of pulmonary embolism: from threat to therapy samuel z. goldhaber, md...
TRANSCRIPT
Optimizing Management of PulmonaryOptimizing Management of PulmonaryEmbolism: From Threat to TherapyEmbolism: From Threat to Therapy
Samuel Z. Goldhaber, MDSamuel Z. Goldhaber, MDCardiovascular DivisionCardiovascular Division
Brigham and Women’s HospitalBrigham and Women’s HospitalProfessor of MedicineProfessor of Medicine
Harvard Medical SchoolHarvard Medical School
Samuel Z. Goldhaber, MDSamuel Z. Goldhaber, MDCardiovascular DivisionCardiovascular Division
Brigham and Women’s HospitalBrigham and Women’s HospitalProfessor of MedicineProfessor of Medicine
Harvard Medical SchoolHarvard Medical School
DVT-WRAP SlideCASTDVT-WRAP SlideCAST
Learning ObjectivesLearning Objectives
► EpidemiologyEpidemiology► DiagnosisDiagnosis► Risk StratificationRisk Stratification► Treatment: Treatment: anticoagulationanticoagulation
thrombolysisthrombolysis
embolectomyembolectomy► PreventionPrevention
► EpidemiologyEpidemiology► DiagnosisDiagnosis► Risk StratificationRisk Stratification► Treatment: Treatment: anticoagulationanticoagulation
thrombolysisthrombolysis
embolectomyembolectomy► PreventionPrevention
EpidemiologyEpidemiology
IncidenceIncidence
• 900,000 PEs/ DVTs in USA in 2002.
• Estimated 296,000 PE deaths:
7% treated, 34% sudden and fatal, and 59% undetected.Heit J. ASH Abstract 2005
----------------------------------------- 762,000 PEs/ DVTs in EU in 2004.Thromb Haemostas 2007; 98: 756
The high death rate from PE (exceeding acute The high death rate from PE (exceeding acute MI!) and the high frequency of undiagnosed PE MI!) and the high frequency of undiagnosed PE causing “sudden cardiac death” emphasize the causing “sudden cardiac death” emphasize the need for need for improved preventive efforts.improved preventive efforts.
Failure to institute prophylaxis is a much bigger Failure to institute prophylaxis is a much bigger problem with Medical Service patients than problem with Medical Service patients than Surgical Service patients.Surgical Service patients.
The high death rate from PE (exceeding acute The high death rate from PE (exceeding acute MI!) and the high frequency of undiagnosed PE MI!) and the high frequency of undiagnosed PE causing “sudden cardiac death” emphasize the causing “sudden cardiac death” emphasize the need for need for improved preventive efforts.improved preventive efforts.
Failure to institute prophylaxis is a much bigger Failure to institute prophylaxis is a much bigger problem with Medical Service patients than problem with Medical Service patients than Surgical Service patients.Surgical Service patients.
Annual At-Risk for VTE:Annual At-Risk for VTE:U.S. HospitalsU.S. Hospitals
► 7.7 million Medical Service inpatients7.7 million Medical Service inpatients
► 3.4 million Surgical Service inpatients 3.4 million Surgical Service inpatients
► Based upon ACCP guidelines for VTE prophylaxisBased upon ACCP guidelines for VTE prophylaxis
► 7.7 million Medical Service inpatients7.7 million Medical Service inpatients
► 3.4 million Surgical Service inpatients 3.4 million Surgical Service inpatients
► Based upon ACCP guidelines for VTE prophylaxisBased upon ACCP guidelines for VTE prophylaxis
Anderson FA Jr, et al. Am J Hematol; 2007; 82: 777-782
Outpatient and Inpatient VTE are LinkedOutpatient and Inpatient VTE are Linked
► 74% of VTEs present in outpatients.74% of VTEs present in outpatients.
► 42% of outpatient VTE patients have had recent 42% of outpatient VTE patients have had recent surgery or hospitalization. surgery or hospitalization.
► Only 40% had received VTE prophylaxis.Only 40% had received VTE prophylaxis.
► 74% of VTEs present in outpatients.74% of VTEs present in outpatients.
► 42% of outpatient VTE patients have had recent 42% of outpatient VTE patients have had recent surgery or hospitalization. surgery or hospitalization.
► Only 40% had received VTE prophylaxis.Only 40% had received VTE prophylaxis.
Spencer FA, et al. Arch Intern Med 2007; 167: 1471-1475
ICOPER Cumulative MortalityICOPER Cumulative MortalityM
ort
alit
y (
%)
Mort
alit
y (
%)
Days From DiagnosisDays From Diagnosis
17.5%17.5%
0
5
10
15
20
25
7 14 30 60 90
Lancet 1999; 353: 1386-1389
Progression of Chronic Venous Insufficiency
From UpToDate 2006
Cardiovascular Risk Factors and VTE Cardiovascular Risk Factors and VTE (N=63,552 meta-analysis)(N=63,552 meta-analysis)
RFRF RRRRObesityObesity 2.32.3
HypertensionHypertension 1.51.5
DiabetesDiabetes 1.41.4
CigarettesCigarettes 1.21.2
High CholesterolHigh Cholesterol 1.21.2
RFRF RRRRObesityObesity 2.32.3
HypertensionHypertension 1.51.5
DiabetesDiabetes 1.41.4
CigarettesCigarettes 1.21.2
High CholesterolHigh Cholesterol 1.21.2
Ageno W. Circulation 2008; 117: 93-102Ageno W. Circulation 2008; 117: 93-102
Steffen LM. CirculationSteffen LM. Circulation 2007;115:188-1952007;115:188-195
Eat Veggies and Lower VTE Risk; Eat Veggies and Lower VTE Risk; Careful with Red MeatCareful with Red Meat
Adjusted Hazard Ratios (Quintiles)2 3 4 5 p
Fruits, veggie
0.73 0.57 0.47 0.59 0.03
Fish 0.58 0.60 0.55 0.70 0.30
Red Meat
1.24 1.21 1.09 2.01 0.02
Dabish 20-Year Cohort: Dabish 20-Year Cohort: VTE, Subsequent CV EventsVTE, Subsequent CV Events
► Assessed risk of MI, StrokeAssessed risk of MI, Stroke
► 25,199 with DVT25,199 with DVT
► 16,925 with PE 16,925 with PE
► 163,566 population controls163,566 population controls
► Assessed risk of MI, StrokeAssessed risk of MI, Stroke
► 25,199 with DVT25,199 with DVT
► 16,925 with PE 16,925 with PE
► 163,566 population controls163,566 population controls
Sorensen HT. Lancet 2007; 370: 1773-1779Sorensen HT. Lancet 2007; 370: 1773-1779
RR CV Event in PE PatientsRR CV Event in PE Patients
CV EventCV Event 1 Year RR1 Year RR 2-20 Year RR2-20 Year RR
Acute MIAcute MI 2.62.6 1.31.3
StrokeStroke 2.92.9 1.31.3
Sorensen HT. Lancet 2007; 370: 1773-1779
Reversible Risk FactorsReversible Risk Factors
1.1. Nutrition: eat fruits, veggies, fish; less red meatNutrition: eat fruits, veggies, fish; less red meat
2.2. Quit cigarettesQuit cigarettes
3.3. Lose weight/ exerciseLose weight/ exercise
4.4. Prevent DM/ metabolic syndromePrevent DM/ metabolic syndrome
5.5. Control hypertension Control hypertension
6.6. Lower cholesterolLower cholesterol
1.1. Nutrition: eat fruits, veggies, fish; less red meatNutrition: eat fruits, veggies, fish; less red meat
2.2. Quit cigarettesQuit cigarettes
3.3. Lose weight/ exerciseLose weight/ exercise
4.4. Prevent DM/ metabolic syndromePrevent DM/ metabolic syndrome
5.5. Control hypertension Control hypertension
6.6. Lower cholesterolLower cholesterol
DIAGNOSISDIAGNOSIS
PE SXS/ Signs (PIOPED II)PE SXS/ Signs (PIOPED II)
► Dyspnea (79%)Dyspnea (79%)
► Tachypnea (57%)Tachypnea (57%)
► Pleuritic pain (47%)Pleuritic pain (47%)
► Leg edema, erythema, tenderness, palpable Leg edema, erythema, tenderness, palpable cord (47%)cord (47%)
► Cough/ hemoptysis (43%)Cough/ hemoptysis (43%)
► Dyspnea (79%)Dyspnea (79%)
► Tachypnea (57%)Tachypnea (57%)
► Pleuritic pain (47%)Pleuritic pain (47%)
► Leg edema, erythema, tenderness, palpable Leg edema, erythema, tenderness, palpable cord (47%)cord (47%)
► Cough/ hemoptysis (43%)Cough/ hemoptysis (43%)
Stein PD. Am J Med 2007; 120: 871-879Stein PD. Am J Med 2007; 120: 871-879
Clinical Decision RuleClinical Decision Rule
JAMA 2006; 295: 172-179JAMA 2006; 295: 172-179
CT Leg Venography & U/S:CT Leg Venography & U/S:Necessary or “Overkill”?Necessary or “Overkill”?
► Incremental value of CTV (N=829): Incremental value of CTV (N=829):
0.7% in low-risk patients and 2.6% in high 0.7% in low-risk patients and 2.6% in high risk patients (prior VTE, cancer). CTV more risk patients (prior VTE, cancer). CTV more than doubles radiation dosethan doubles radiation dose
(Hunsaker. AJR 2008; 190: 322-328)(Hunsaker. AJR 2008; 190: 322-328)
► Chest CT alone (N=1,819) was noninferior to Chest CT alone (N=1,819) was noninferior to chest CT plus leg U/S. (Lancet 2008; 371: chest CT plus leg U/S. (Lancet 2008; 371: 1343-1352)1343-1352)
► Incremental value of CTV (N=829): Incremental value of CTV (N=829):
0.7% in low-risk patients and 2.6% in high 0.7% in low-risk patients and 2.6% in high risk patients (prior VTE, cancer). CTV more risk patients (prior VTE, cancer). CTV more than doubles radiation dosethan doubles radiation dose
(Hunsaker. AJR 2008; 190: 322-328)(Hunsaker. AJR 2008; 190: 322-328)
► Chest CT alone (N=1,819) was noninferior to Chest CT alone (N=1,819) was noninferior to chest CT plus leg U/S. (Lancet 2008; 371: chest CT plus leg U/S. (Lancet 2008; 371: 1343-1352)1343-1352)
Saddle EmbolusSaddle Embolus
PE DiagnosisPE Diagnosis
Suspect PE: CXR, ECG, Oximetry
CDR < 4 CDR > 4
Chest CTD-dimer
Pos: Rx for PEHigh: get CT
Neg: stop W/UNormal: stop W/U
Risk StratificationRisk Stratification
Risk StratificationRisk Stratification: PE: PEis is essentialessential to decide: to decide:
1.1. Anticoagulation Anticoagulation alonealone versusversus anticoagulation anticoagulation plusplus thrombolysis/ thrombolysis/ embolectomyembolectomy
2.2. Triage to Intensive Care UnitTriage to Intensive Care Unit
3.3. Consider RFs for fatal PE: massive PE, Consider RFs for fatal PE: massive PE, immobilization, age immobilization, age > > 75 years, cancer. 75 years, cancer.
Risk StratificationRisk Stratification: PE: PEis is essentialessential to decide: to decide:
1.1. Anticoagulation Anticoagulation alonealone versusversus anticoagulation anticoagulation plusplus thrombolysis/ thrombolysis/ embolectomyembolectomy
2.2. Triage to Intensive Care UnitTriage to Intensive Care Unit
3.3. Consider RFs for fatal PE: massive PE, Consider RFs for fatal PE: massive PE, immobilization, age immobilization, age > > 75 years, cancer. 75 years, cancer.
Circulation 2008; 117: 1711-1716
TROPONIN META-ANALYSIS: Indicates RV TROPONIN META-ANALYSIS: Indicates RV Micro Infarct (Even “Leaks” Are Important)Micro Infarct (Even “Leaks” Are Important)
► 1,985 patients from 20 PE studies 1,985 patients from 20 PE studies
► 20%20% of 618 with of 618 with elevated levels diedelevated levels died
► 3.7%3.7% of 1,367 with of 1,367 with WNL levels diedWNL levels died
► In hemodynamically stable PE patients, In hemodynamically stable PE patients, elevated troponin levels elevated troponin levels increased mortality increased mortality 6-fold.6-fold.
► 1,985 patients from 20 PE studies 1,985 patients from 20 PE studies
► 20%20% of 618 with of 618 with elevated levels diedelevated levels died
► 3.7%3.7% of 1,367 with of 1,367 with WNL levels diedWNL levels died
► In hemodynamically stable PE patients, In hemodynamically stable PE patients, elevated troponin levels elevated troponin levels increased mortality increased mortality 6-fold.6-fold.
Circulation 2007; 116: 427-433Circulation 2007; 116: 427-433
Risk Stratify PE:Risk Stratify PE:Assess RV Size, FunctionAssess RV Size, Function
► ECHO:ECHO: RV/LV EDD RV/LV EDD >> 0.9 predicts 0.9 predicts increased hospital mortality (OR=2.6) increased hospital mortality (OR=2.6)
(Fremont B. CHEST 2008;133: 358) and (Fremont B. CHEST 2008;133: 358) and recurrent (often fatal) PErecurrent (often fatal) PE
(Arch Intern Med 2006; 166: 2151)(Arch Intern Med 2006; 166: 2151)► Chest CT:Chest CT: an alternative to ECHO to an alternative to ECHO to
compare RV/LV sizecompare RV/LV size
► ECHO:ECHO: RV/LV EDD RV/LV EDD >> 0.9 predicts 0.9 predicts increased hospital mortality (OR=2.6) increased hospital mortality (OR=2.6)
(Fremont B. CHEST 2008;133: 358) and (Fremont B. CHEST 2008;133: 358) and recurrent (often fatal) PErecurrent (often fatal) PE
(Arch Intern Med 2006; 166: 2151)(Arch Intern Med 2006; 166: 2151)► Chest CT:Chest CT: an alternative to ECHO to an alternative to ECHO to
compare RV/LV sizecompare RV/LV size
RV ENLARGEMENT: RV ENLARGEMENT: CHEST CTCHEST CT
Circulation 2004; 110: 3276Circulation 2004; 110: 3276Circulation 2004; 110: 3276Circulation 2004; 110: 3276
TreatmentTreatment
VTE: Immediate AnticoagulationVTE: Immediate Anticoagulation
1.1. Unfractionated heparin: target PTT between Unfractionated heparin: target PTT between 60 to 80 seconds60 to 80 seconds
2.2. Low molecular weight heparins: enoxaparin, Low molecular weight heparins: enoxaparin, dalteparin, tinzaparindalteparin, tinzaparin
3.3. FondaparinuxFondaparinux
4.4. Direct thrombin inhibitors (HIT): argatroban, Direct thrombin inhibitors (HIT): argatroban, lepirudin, bivalirudinlepirudin, bivalirudin
1.1. Unfractionated heparin: target PTT between Unfractionated heparin: target PTT between 60 to 80 seconds60 to 80 seconds
2.2. Low molecular weight heparins: enoxaparin, Low molecular weight heparins: enoxaparin, dalteparin, tinzaparindalteparin, tinzaparin
3.3. FondaparinuxFondaparinux
4.4. Direct thrombin inhibitors (HIT): argatroban, Direct thrombin inhibitors (HIT): argatroban, lepirudin, bivalirudinlepirudin, bivalirudin
Cancer and VTECancer and VTE
► 3-fold higher recurrence and bleeding,3-fold higher recurrence and bleeding, when treating cancer patients (Prandoni. when treating cancer patients (Prandoni. Blood 2002; 100: 3484)Blood 2002; 100: 3484)
► LMWH MonotherapyLMWH Monotherapy halves recurrence, halves recurrence, compared with warfarin. compared with warfarin.
(Lee AYY. NEJM 2003; 349:146)(Lee AYY. NEJM 2003; 349:146)
(FDA approved May 2007)(FDA approved May 2007)
► 3-fold higher recurrence and bleeding,3-fold higher recurrence and bleeding, when treating cancer patients (Prandoni. when treating cancer patients (Prandoni. Blood 2002; 100: 3484)Blood 2002; 100: 3484)
► LMWH MonotherapyLMWH Monotherapy halves recurrence, halves recurrence, compared with warfarin. compared with warfarin.
(Lee AYY. NEJM 2003; 349:146)(Lee AYY. NEJM 2003; 349:146)
(FDA approved May 2007)(FDA approved May 2007)
Aggressive VTE TherapyAggressive VTE Therapy
► Surgical embolectomySurgical embolectomy
(Stein PD. Am J Cardiol 2007; 99: 421)(Stein PD. Am J Cardiol 2007; 99: 421)► Catheter embolectomyCatheter embolectomy
(Kucher N. CHEST 2007; 132: 657-663)(Kucher N. CHEST 2007; 132: 657-663)► PE ThrombolysisPE Thrombolysis
(Wan S. Circulation 2004; 110: 744)(Wan S. Circulation 2004; 110: 744)► Catheter-based DVT therapiesCatheter-based DVT therapies
(Chang R. Radiology 2008; 246: 619)(Chang R. Radiology 2008; 246: 619)
(Vasc Interv Radiol 2008; 19: 372-376)(Vasc Interv Radiol 2008; 19: 372-376)
► Surgical embolectomySurgical embolectomy
(Stein PD. Am J Cardiol 2007; 99: 421)(Stein PD. Am J Cardiol 2007; 99: 421)► Catheter embolectomyCatheter embolectomy
(Kucher N. CHEST 2007; 132: 657-663)(Kucher N. CHEST 2007; 132: 657-663)► PE ThrombolysisPE Thrombolysis
(Wan S. Circulation 2004; 110: 744)(Wan S. Circulation 2004; 110: 744)► Catheter-based DVT therapiesCatheter-based DVT therapies
(Chang R. Radiology 2008; 246: 619)(Chang R. Radiology 2008; 246: 619)
(Vasc Interv Radiol 2008; 19: 372-376)(Vasc Interv Radiol 2008; 19: 372-376)
47 EMERGENCY EMBOLECTOMIES
Survival = 94 %
J Thorac Cardiovasc Surg 2005;129:1018
N=47
Surgical Embolectomy at BWH:Surgical Embolectomy at BWH:Surgeon’s Cell PhoneSurgeon’s Cell Phone
PE Thrombectomy DevicePE Thrombectomy Device
Dimension: 11 French
Spiral CoilSuction Ports
Heparin “Catches Up” with Lysis: Heparin “Catches Up” with Lysis: Lung PerfusionLung Perfusion
Arch Intern Med 1997; 157: 2550
ThrombolysisThrombolysis in submassive PE remains in submassive PE remains controversial.controversial.
A multinational European clinical trial (85 centers/ 12 A multinational European clinical trial (85 centers/ 12 countries) will enroll about 1,100 countries) will enroll about 1,100 submassive submassive PEPE patients with normal BP, elevated Troponin, patients with normal BP, elevated Troponin, and RV enlargement on ECHO. Reduce death/ and RV enlargement on ECHO. Reduce death/ CV collapse from 12.9% to 7.6% in 1 week? CV collapse from 12.9% to 7.6% in 1 week?
(1(1stst patient enrolled 11/10/2007; 65 patient enrolled 11/10/2007; 65 thth on 8/25/2008) on 8/25/2008)
ThrombolysisThrombolysis in submassive PE remains in submassive PE remains controversial.controversial.
A multinational European clinical trial (85 centers/ 12 A multinational European clinical trial (85 centers/ 12 countries) will enroll about 1,100 countries) will enroll about 1,100 submassive submassive PEPE patients with normal BP, elevated Troponin, patients with normal BP, elevated Troponin, and RV enlargement on ECHO. Reduce death/ and RV enlargement on ECHO. Reduce death/ CV collapse from 12.9% to 7.6% in 1 week? CV collapse from 12.9% to 7.6% in 1 week?
(1(1stst patient enrolled 11/10/2007; 65 patient enrolled 11/10/2007; 65 thth on 8/25/2008) on 8/25/2008)
LYSIS VS. Filter: Massive PELYSIS VS. Filter: Massive PE(N=108)(N=108)
Lysis
Lysis
Filter
Filter
8 YEAR F/U IVC FILTERS: RCT8 YEAR F/U IVC FILTERS: RCT
PREPIC. Circulation 2005; 112: 416-422PREPIC. Circulation 2005; 112: 416-422
BARDBARDRECOVERY RECOVERY
FILTERFILTER
RATE OF RECURRENT VTE
(Arch Intern Med 2000; 160: 761-768)
Olmsted County
5%
10%13%
30%
0%
5%
10%
15%
20%
25%
30%
35%
1/12 1/2 1 10
Number of Years
//
Risks for Recurrence Risks for Recurrence
► ““Unprovoked”Unprovoked”
► Strong FH; PMH of VTEStrong FH; PMH of VTE
► Antiphospholipid antibody syndromeAntiphospholipid antibody syndrome
► CancerCancer
► Male (Kyrle PA. NEJM 2004; 350: 2558) (McRae S. Male (Kyrle PA. NEJM 2004; 350: 2558) (McRae S. Lancet 2006; 368: 371-8)Lancet 2006; 368: 371-8)
► Presentation with PE Symptoms Presentation with PE Symptoms
► ““Unprovoked”Unprovoked”
► Strong FH; PMH of VTEStrong FH; PMH of VTE
► Antiphospholipid antibody syndromeAntiphospholipid antibody syndrome
► CancerCancer
► Male (Kyrle PA. NEJM 2004; 350: 2558) (McRae S. Male (Kyrle PA. NEJM 2004; 350: 2558) (McRae S. Lancet 2006; 368: 371-8)Lancet 2006; 368: 371-8)
► Presentation with PE Symptoms Presentation with PE Symptoms
Eichinger. Arch Intern Med 2004;164: 92)
Trials of Unprovoked VTE : Favor Indefinite Trials of Unprovoked VTE : Favor Indefinite Duration Anticoagulation (NEJM 2003)Duration Anticoagulation (NEJM 2003)
TRIALTRIAL TAKE-HOME POINT TAKE-HOME POINT ..
PREVENTPREVENT Low intensity A/C (INR Low intensity A/C (INR 1.5-2.0) reduces recurrence 1.5-2.0) reduces recurrence rate by 2/3.rate by 2/3.
ELATEELATE Standard A/C (INR 2.0-3.0) Standard A/C (INR 2.0-3.0) is is more effective but as safe as more effective but as safe as low intensity A/C.low intensity A/C.
THRIVE-3THRIVE-3 Ximelagatran effective, safe.Ximelagatran effective, safe.
TRIALTRIAL TAKE-HOME POINT TAKE-HOME POINT ..
PREVENTPREVENT Low intensity A/C (INR Low intensity A/C (INR 1.5-2.0) reduces recurrence 1.5-2.0) reduces recurrence rate by 2/3.rate by 2/3.
ELATEELATE Standard A/C (INR 2.0-3.0) Standard A/C (INR 2.0-3.0) is is more effective but as safe as more effective but as safe as low intensity A/C.low intensity A/C.
THRIVE-3THRIVE-3 Ximelagatran effective, safe.Ximelagatran effective, safe.
Does Thrombophilia Predict Recurrent VTE?Does Thrombophilia Predict Recurrent VTE?
► 474 VTE patients followed for an average of 7 years.474 VTE patients followed for an average of 7 years.
► Most patients were anticoagulated for Most patients were anticoagulated for << 12 months. 12 months.
► 90 (20%) suffered recurrence.90 (20%) suffered recurrence.
► Thrombophilia did Thrombophilia did notnot increase likelihood of increase likelihood of
recurrencerecurrence..
► 474 VTE patients followed for an average of 7 years.474 VTE patients followed for an average of 7 years.
► Most patients were anticoagulated for Most patients were anticoagulated for << 12 months. 12 months.
► 90 (20%) suffered recurrence.90 (20%) suffered recurrence.
► Thrombophilia did Thrombophilia did notnot increase likelihood of increase likelihood of
recurrencerecurrence..
Christiansen SC. JAMA 2005; 293: 2352Christiansen SC. JAMA 2005; 293: 2352
How Often and For How Long Does How Often and For How Long Does CT Remain Abnormal After PE?CT Remain Abnormal After PE?
F/U ABNORMAL
6 Weeks 68%
3 Months 65%
6 Months 57%
11 Months 52%
Nijkeuter M. CHEST 2006; 129: 192-197Nijkeuter M. CHEST 2006; 129: 192-197
Warfarin PharmacogenomicsWarfarin Pharmacogenomics
1.1. Cytochrome P450 2C9 genotyping can identify Cytochrome P450 2C9 genotyping can identify mutations associated with impaired warfarin mutations associated with impaired warfarin metabolism.metabolism.
2.2. Vitamin K receptor polymorphism testing can Vitamin K receptor polymorphism testing can identify whether patients require low, intermediate, identify whether patients require low, intermediate,
or high doses of warfarinor high doses of warfarin..
1.1. Cytochrome P450 2C9 genotyping can identify Cytochrome P450 2C9 genotyping can identify mutations associated with impaired warfarin mutations associated with impaired warfarin metabolism.metabolism.
2.2. Vitamin K receptor polymorphism testing can Vitamin K receptor polymorphism testing can identify whether patients require low, intermediate, identify whether patients require low, intermediate,
or high doses of warfarinor high doses of warfarin..
Schwartz UI. NEJM 2008; 358: 999Schwartz UI. NEJM 2008; 358: 999
► Rapid turnaround CYP2C9 and VKORC1 testing Rapid turnaround CYP2C9 and VKORC1 testing vs. “empiric”vs. “empiric”
► Primary endpoint: TTR Primary endpoint: TTR
► Smaller and fewer dosing changes with genetic Smaller and fewer dosing changes with genetic testing testing
► No difference in TTRNo difference in TTR
► Rapid turnaround CYP2C9 and VKORC1 testing Rapid turnaround CYP2C9 and VKORC1 testing vs. “empiric”vs. “empiric”
► Primary endpoint: TTR Primary endpoint: TTR
► Smaller and fewer dosing changes with genetic Smaller and fewer dosing changes with genetic testing testing
► No difference in TTRNo difference in TTR
Genotype vs Standard Warfarin Dosing Genotype vs Standard Warfarin Dosing (n=206) (n=206)
Couma-Gen TrialCouma-Gen Trial
Circulation 2007; 116: 2563-2570Circulation 2007; 116: 2563-2570
Self-Monitoring INR: Meta-Analysis of 14 RCTSSelf-Monitoring INR: Meta-Analysis of 14 RCTS
► Reduced TE events (55% fewer)Reduced TE events (55% fewer)► Reduced all-cause mortality (39% less)Reduced all-cause mortality (39% less)► Reduced major bleeds (35% fewer)Reduced major bleeds (35% fewer)
Benefits increase further with self-dosingBenefits increase further with self-dosing► 73% fewer TE events73% fewer TE events► 63% lower all-cause mortality63% lower all-cause mortality
Heneghan C. Lancet 2006; 367: 404-411Heneghan C. Lancet 2006; 367: 404-411
► Reduced TE events (55% fewer)Reduced TE events (55% fewer)► Reduced all-cause mortality (39% less)Reduced all-cause mortality (39% less)► Reduced major bleeds (35% fewer)Reduced major bleeds (35% fewer)
Benefits increase further with self-dosingBenefits increase further with self-dosing► 73% fewer TE events73% fewer TE events► 63% lower all-cause mortality63% lower all-cause mortality
Heneghan C. Lancet 2006; 367: 404-411Heneghan C. Lancet 2006; 367: 404-411
March 19, 2008: Medicare Expanded March 19, 2008: Medicare Expanded Reimbursement for Home INR MonitoringReimbursement for Home INR Monitoring
► Medicare used to cover only mechanical Medicare used to cover only mechanical heart valvesheart valves
► Now will reimburse VTE (after 3 months Now will reimburse VTE (after 3 months of warfarin) and chronic atrial fibrillationof warfarin) and chronic atrial fibrillation
► Aetna follows new Medicare guidelines Aetna follows new Medicare guidelines (and surely others will, too) (and surely others will, too)
► Medicare used to cover only mechanical Medicare used to cover only mechanical heart valvesheart valves
► Now will reimburse VTE (after 3 months Now will reimburse VTE (after 3 months of warfarin) and chronic atrial fibrillationof warfarin) and chronic atrial fibrillation
► Aetna follows new Medicare guidelines Aetna follows new Medicare guidelines (and surely others will, too) (and surely others will, too)
Novel Oral AnticoagulantsNovel Oral Anticoagulants
1.1. Dabigatran:Dabigatran: an oral DTI—twice daily fixed dose an oral DTI—twice daily fixed dose (renal clearance)(renal clearance)
2.2. Rivaroxaban:Rivaroxaban: direct factor Xa inhibitor (renal direct factor Xa inhibitor (renal clearance)—once daily fixed doseclearance)—once daily fixed dose
3.3. Apixaban:Apixaban: direct factor Xa inhibitor (hepatic direct factor Xa inhibitor (hepatic clearance)—twice daily fixed doseclearance)—twice daily fixed dose
1.1. Dabigatran:Dabigatran: an oral DTI—twice daily fixed dose an oral DTI—twice daily fixed dose (renal clearance)(renal clearance)
2.2. Rivaroxaban:Rivaroxaban: direct factor Xa inhibitor (renal direct factor Xa inhibitor (renal clearance)—once daily fixed doseclearance)—once daily fixed dose
3.3. Apixaban:Apixaban: direct factor Xa inhibitor (hepatic direct factor Xa inhibitor (hepatic clearance)—twice daily fixed doseclearance)—twice daily fixed dose
Gross PL, Weitz JI; ATVB 2008; 28: 380)Gross PL, Weitz JI; ATVB 2008; 28: 380)
PreventionPrevention
VTE Prophylaxis in 19,958 Medical Patients/VTE Prophylaxis in 19,958 Medical Patients/9 Studies (Meta-Analysis)9 Studies (Meta-Analysis)
► 62% reduction in fatal PE62% reduction in fatal PE
► 57% reduction in fatal or nonfatal PE57% reduction in fatal or nonfatal PE
► 53% reduction in DVT53% reduction in DVT
► 62% reduction in fatal PE62% reduction in fatal PE
► 57% reduction in fatal or nonfatal PE57% reduction in fatal or nonfatal PE
► 53% reduction in DVT53% reduction in DVT
Dentali F, et al. Ann Intern Med 2007; 146: 278-288Dentali F, et al. Ann Intern Med 2007; 146: 278-288
Hull RD et al. July 2007; ISTH; Geneva
EXCLAIM: Extended-Duration Enoxaparin EXCLAIM: Extended-Duration Enoxaparin Prophylaxis in High-Risk Medical PatientsProphylaxis in High-Risk Medical Patients
End pointsEnd points Outcome, Outcome, extended extended
prophylaxis, prophylaxis, n=2052 (%)n=2052 (%)
Outcome, Outcome, placebo, placebo, n=2062 n=2062
(%)(%)
RR RR reduction reduction
(%)(%)
pp
VTE eventsVTE events 2.82.8 4.94.9 44%44% 0.0010.001
SymptomaticSymptomatic 0.30.3 1.11.1 73%73% 0.0040.004
No SxsNo Sxs 2.52.5 3.73.7 34%34% 0.0320.032
The Amin Report: The Amin Report: Prophylaxis Rates in the USProphylaxis Rates in the US
► Studied 196,104 Medical Service discharges from Studied 196,104 Medical Service discharges from 227 hospitals (Premier227 hospitals (Premier® database)® database)..
► VTE prophylaxis rate was 62%.VTE prophylaxis rate was 62%.
► ACCP-deemed appropriate prophylaxis rate was ACCP-deemed appropriate prophylaxis rate was 34%.34%.
► Studied 196,104 Medical Service discharges from Studied 196,104 Medical Service discharges from 227 hospitals (Premier227 hospitals (Premier® database)® database)..
► VTE prophylaxis rate was 62%.VTE prophylaxis rate was 62%.
► ACCP-deemed appropriate prophylaxis rate was ACCP-deemed appropriate prophylaxis rate was 34%.34%.
J Thromb Haemostas 2007; 5: 1610-6J Thromb Haemostas 2007; 5: 1610-6
Medical Patient Prophylaxis in CanadaMedical Patient Prophylaxis in Canada
► Studied 1,894 Medical Service discharges from 29 Studied 1,894 Medical Service discharges from 29 hospitals.hospitals.
► VTE prophylaxis was indicated in 90% of patients. VTE prophylaxis was indicated in 90% of patients.
► ACCP-deemed appropriate prophylaxis rate was ACCP-deemed appropriate prophylaxis rate was 16%.16%.
► Studied 1,894 Medical Service discharges from 29 Studied 1,894 Medical Service discharges from 29 hospitals.hospitals.
► VTE prophylaxis was indicated in 90% of patients. VTE prophylaxis was indicated in 90% of patients.
► ACCP-deemed appropriate prophylaxis rate was ACCP-deemed appropriate prophylaxis rate was 16%.16%.
Thrombosis Research 2007; 119: 145-155
ENDORSE : WORLDWIDE ENDORSE : WORLDWIDE (Lancet 2008; 371: 387-394)(Lancet 2008; 371: 387-394)
68,183 patients; 32 countries; 358 sites68,183 patients; 32 countries; 358 sitesFirst patient enrolled August 2, 2006;Last patient enrolled January 4, 2007First patient enrolled August 2, 2006;Last patient enrolled January 4, 2007
42% at Risk for VTE
Medical
40% receive ACCPRec. Px
64% at Risk for VTE
59% receive ACCPRec. Px
Surgical
Worldwide Prophylaxis Status Worldwide Prophylaxis Status for 68,183 Patientsfor 68,183 Patients
52% at Risk for VTE
(50% receive ACCPrecommended prophy)
We have initiated trials to We have initiated trials to modify MD behaviormodify MD behavior and improve and improve implementation implementation of VTE prophylaxisof VTE prophylaxis—not trials of specific types of prophylaxis——not trials of specific types of prophylaxis—electronic alerts and human alerts.electronic alerts and human alerts.
We have initiated trials to We have initiated trials to modify MD behaviormodify MD behavior and improve and improve implementation implementation of VTE prophylaxisof VTE prophylaxis—not trials of specific types of prophylaxis——not trials of specific types of prophylaxis—electronic alerts and human alerts.electronic alerts and human alerts.
Definition of “High Risk”Definition of “High Risk”
VTE risk score ≥ 4 points:VTE risk score ≥ 4 points:► CancerCancer 33 (ICD codes)(ICD codes)► Prior VTEPrior VTE 33 (ICD codes)(ICD codes)► HypercoagulabilityHypercoagulability 33 (Leiden, ACLA)(Leiden, ACLA)► Major surgeryMajor surgery 22 (> 60 minutes)(> 60 minutes)► Bed restBed rest 11 (“bed rest” order)(“bed rest” order)► Advanced ageAdvanced age 11 (> 70 years)(> 70 years)► ObesityObesity 11 (BMI > 29 kg/m(BMI > 29 kg/m22))► HRT/OCHRT/OC 11 (order entry)(order entry)
VTE risk score ≥ 4 points:VTE risk score ≥ 4 points:► CancerCancer 33 (ICD codes)(ICD codes)► Prior VTEPrior VTE 33 (ICD codes)(ICD codes)► HypercoagulabilityHypercoagulability 33 (Leiden, ACLA)(Leiden, ACLA)► Major surgeryMajor surgery 22 (> 60 minutes)(> 60 minutes)► Bed restBed rest 11 (“bed rest” order)(“bed rest” order)► Advanced ageAdvanced age 11 (> 70 years)(> 70 years)► ObesityObesity 11 (BMI > 29 kg/m(BMI > 29 kg/m22))► HRT/OCHRT/OC 11 (order entry)(order entry)
RandomizationRandomization
VTE risk score > 4
No prophylaxis
N = 2,506
INTERVENTION:
Single alert
N = 1,255
CONTROL
No computer alert
N = 1,251
Kucher N, et al. NEJM 2005;352:969-977Kucher N, et al. NEJM 2005;352:969-977
90-Day Primary Endpoint90-Day Primary Endpoint
Intervent.Intervent. ControlControl Hazard RatioHazard Ratio pp
N=1255 N=1251 (95% CI)N=1255 N=1251 (95% CI)
Total VTE 61 (4.9) 103 (8.2) Total VTE 61 (4.9) 103 (8.2) 0.590.59 (0.43-0.81) (0.43-0.81) 0.0010.001
Acute PE 14 (1.1) 35 (2.8) Acute PE 14 (1.1) 35 (2.8) 0.400.40 (0.21-0.74) (0.21-0.74) 0.0040.004
Proximal DVT 10 (0.8) 23 (1.8) Proximal DVT 10 (0.8) 23 (1.8) 0.470.47 (0.20-1.09) (0.20-1.09) 0.080.08
Distal DVT 5 (0.4) 12 (1.0) 0.42 (0.15-1.18) 0.10Distal DVT 5 (0.4) 12 (1.0) 0.42 (0.15-1.18) 0.10
UE DVT 32 (2.5) 33 (2.6) 0.97 (0.60-1.58) 0.90UE DVT 32 (2.5) 33 (2.6) 0.97 (0.60-1.58) 0.90
Intervent.Intervent. ControlControl Hazard RatioHazard Ratio pp
N=1255 N=1251 (95% CI)N=1255 N=1251 (95% CI)
Total VTE 61 (4.9) 103 (8.2) Total VTE 61 (4.9) 103 (8.2) 0.590.59 (0.43-0.81) (0.43-0.81) 0.0010.001
Acute PE 14 (1.1) 35 (2.8) Acute PE 14 (1.1) 35 (2.8) 0.400.40 (0.21-0.74) (0.21-0.74) 0.0040.004
Proximal DVT 10 (0.8) 23 (1.8) Proximal DVT 10 (0.8) 23 (1.8) 0.470.47 (0.20-1.09) (0.20-1.09) 0.080.08
Distal DVT 5 (0.4) 12 (1.0) 0.42 (0.15-1.18) 0.10Distal DVT 5 (0.4) 12 (1.0) 0.42 (0.15-1.18) 0.10
UE DVT 32 (2.5) 33 (2.6) 0.97 (0.60-1.58) 0.90UE DVT 32 (2.5) 33 (2.6) 0.97 (0.60-1.58) 0.90
Kucher N, et al. NEJM 2005;352:969-977Kucher N, et al. NEJM 2005;352:969-977
Primary End PointPrimary End Point
InterventionInterventionControlControl
NNumberumber at risk at risk12551255 977977 900900 85385312511251 976976 893893 839839
InterventionIntervention
Control Control
Time Time ((daysdays))00 3030 6060 9090%
Freedom
fro
m D
VT/
%Fr
eedom
fro
m D
VT/ PEPE
9090
9292
9494
9696
9898
100100
Kucher N, et al. NEJM 2005;352:969-977Kucher N, et al. NEJM 2005;352:969-977
““Take Home” PointsTake Home” Points
1.1. VTE causes CVI, pulmonary hypertension, VTE causes CVI, pulmonary hypertension, disability, and death.disability, and death.
2.2. Diagnose PE: CDR, D-dimer, CT. Diagnose PE: CDR, D-dimer, CT.
3.3. Risk stratify PE patients: clinical evaluation, Risk stratify PE patients: clinical evaluation, biomarkers, RV size/ function (ECHO/ CT)biomarkers, RV size/ function (ECHO/ CT)—”window into future,” even if patient appears —”window into future,” even if patient appears stable.stable.
4.4. Thrombolysis remains controversial.Thrombolysis remains controversial.
5.5. Consider indefinite duration anticoagulation for Consider indefinite duration anticoagulation for idiopathic VTEidiopathic VTE
6.6. Prophylaxis against PE/ DVT is crucial.Prophylaxis against PE/ DVT is crucial.
1.1. VTE causes CVI, pulmonary hypertension, VTE causes CVI, pulmonary hypertension, disability, and death.disability, and death.
2.2. Diagnose PE: CDR, D-dimer, CT. Diagnose PE: CDR, D-dimer, CT.
3.3. Risk stratify PE patients: clinical evaluation, Risk stratify PE patients: clinical evaluation, biomarkers, RV size/ function (ECHO/ CT)biomarkers, RV size/ function (ECHO/ CT)—”window into future,” even if patient appears —”window into future,” even if patient appears stable.stable.
4.4. Thrombolysis remains controversial.Thrombolysis remains controversial.
5.5. Consider indefinite duration anticoagulation for Consider indefinite duration anticoagulation for idiopathic VTEidiopathic VTE
6.6. Prophylaxis against PE/ DVT is crucial.Prophylaxis against PE/ DVT is crucial.
Which Risk Factor is Most Predictive of Recurrent Which Risk Factor is Most Predictive of Recurrent VTE (After Stopping Anticoagulation)?VTE (After Stopping Anticoagulation)?
1.1. Factor V LeidenFactor V Leiden
2.2. Prothrombin gene mutationProthrombin gene mutation
3.3. Postoperative statePostoperative state
4.4. Unprovoked, idiopathic VTE—etiology unknownUnprovoked, idiopathic VTE—etiology unknown
5.5. Birth control or pregnancy associated Birth control or pregnancy associated
1.1. Factor V LeidenFactor V Leiden
2.2. Prothrombin gene mutationProthrombin gene mutation
3.3. Postoperative statePostoperative state
4.4. Unprovoked, idiopathic VTE—etiology unknownUnprovoked, idiopathic VTE—etiology unknown
5.5. Birth control or pregnancy associated Birth control or pregnancy associated
Which Parameter is Most Predictive of a Benign Which Parameter is Most Predictive of a Benign Clinical Course After Diagnosis of PE?Clinical Course After Diagnosis of PE?
1.1. Systolic BP between 110-130 mm HgSystolic BP between 110-130 mm Hg
2.2. HR between 60-80 bpmHR between 60-80 bpm
3.3. RR between 12-16/minuteRR between 12-16/minute
4.4. Normal right ventricular size and function Normal right ventricular size and function on ECHO or CTon ECHO or CT
5.5. Absence of dyspnea or chest painAbsence of dyspnea or chest pain
1.1. Systolic BP between 110-130 mm HgSystolic BP between 110-130 mm Hg
2.2. HR between 60-80 bpmHR between 60-80 bpm
3.3. RR between 12-16/minuteRR between 12-16/minute
4.4. Normal right ventricular size and function Normal right ventricular size and function on ECHO or CTon ECHO or CT
5.5. Absence of dyspnea or chest painAbsence of dyspnea or chest pain